National Healthy Longevity Trial Receives Federal Support

Healthy Longevity, VITAL-H Trial, ARPA-H Funding, Aging Research, Healthspan, Intrinsic Capacity, Geriatric Medicine, Preventive Care, FDA-Approved Drugs, Clinical Trials, healthy longevity clinical trial, aging research funding, ARPA-H PROSPR program, VITAL-H study, healthspan interventions, intrinsic capacity aging, FDA-approved drugs aging, rapamycin longevity, semaglutide aging, dapagliflozin healthspan, geriatric clinical trials, preventive aging medicine, wearable health monitoring, midlife aging study, longevity science

Key Summary Up to $38 million in federal funding awarded to the Barshop Institute at UT Health San Antonio Supports…

Vascular Health Linked to Early Alzheimer’s Brain Changes

Red Blood Cells Improve Glucose Tolerance Under Hypoxia

SARS-CoV-2, COVID-19, rhinovirus, common cold, pediatric COVID, HEROS study, interferon response, respiratory viruses, viral interference, immune priming, National Jewish Health, COVID protection, children immunity, respiratory infections, non-invasive research

Study Reveals Cold May Impact SARS-CoV-2 Infection Rates

The Unexpected Protective Role of Rhinoviruses in COVID-19 A groundbreaking study from National Jewish Health.

COVID-19

Heart, Lung, & Brain Risks Persist in COVID-19 Survivors

A French nationwide study reveals that individuals hospitalized with COVID-19 remain at an increased risk.

vaccines

How COVID-19 and Vaccines Differ in Heart Inflammation

A team of international researchers led by the Max Delbrück Center for Molecular Medicine in.

Long Covid

Long COVID: Extended Paxlovid Treatment Offers Hope

A new case series by UC San Francisco (UCSF) suggests that an extended course of.

COVID-19

SARS-CoV-2, COVID-19, rhinovirus, common cold, pediatric COVID, HEROS study, interferon response, respiratory viruses, viral interference, immune priming, National Jewish Health, COVID protection, children immunity, respiratory infections, non-invasive research

Study Reveals Cold May Impact SARS-CoV-2 Infection Rates

The Unexpected Protective Role of Rhinoviruses in COVID-19 A groundbreaking study from National Jewish Health has revealed an intriguing phenomenon:…

Heart, Lung, & Brain Risks Persist in COVID-19 Survivors

A French nationwide study reveals that individuals hospitalized with COVID-19 remain at an increased risk of death and organ-related complications…

How COVID-19 and Vaccines Differ in Heart Inflammation

A team of international researchers led by the Max Delbrück Center for Molecular Medicine in Berlin has identified distinct immune…

Health and Wellness

Healthy Longevity, VITAL-H Trial, ARPA-H Funding, Aging Research, Healthspan, Intrinsic Capacity, Geriatric Medicine, Preventive Care, FDA-Approved Drugs, Clinical Trials, healthy longevity clinical trial, aging research funding, ARPA-H PROSPR program, VITAL-H study, healthspan interventions, intrinsic capacity aging, FDA-approved drugs aging, rapamycin longevity, semaglutide aging, dapagliflozin healthspan, geriatric clinical trials, preventive aging medicine, wearable health monitoring, midlife aging study, longevity science

National Healthy Longevity Trial Receives Federal Support

Key Summary Up to $38 million in federal funding awarded to the Barshop Institute at UT Health San Antonio Supports…

Vascular Health Linked to Early Alzheimer’s Brain Changes

Key Takeaways Brain vascular health is strongly linked to early Alzheimer’s-related brain changes. Noninvasive measures of blood flow and oxygenation…

Red Blood Cells Improve Glucose Tolerance Under Hypoxia

Key Takeaways for Clinicians Chronic hypoxia lowers fasting glucose and improves glucose tolerance independent of insulin Red Blood Cells (RBCs)…